[ad_1]
A spokesman for Valneva said the firm was “exploring options for its Almeida manufacturing facility in Livingston, initially built to produce its Covid-19 vaccine, including a possible sale or a repurposing to produce its vaccine for Japanese Encephalitis, and its chikungunya vaccine, if approved”.
[ad_2]
Source link
